Evista: Help for Breast Cancer, Heart?
Researcher Says Study on Benefits for Osteoporosis Drug Are 'Disappointing'
WebMD News Archive
The RUTH trial results may serve to dampen the optimism that surrounded
Evista following the release of another study three months ago.
The Study of Tamoxifen and Raloxifene (STAR) trial -- one of the largest
breast cancer prevention trials ever conducted -- found Evista to be as
effective as tamoxifen for preventing breast cancers.
And unlike tamoxifen, Evista did not increase the risk of developing uterine
cancers. There was also some suggestion that Evista was safer in terms of blood
clot and cataract risk. The two treatment groups had roughly the same incidence
of strokes, heart attacks, and bone fractures.
At the time, STAR researcher D. Lawrence Wickerham, MD, called Evista the
clear "winner" of the head-to-head comparison trial.
But women's health researcher Marcia Stefanick, PhD, of Stanford University,
says the STAR trial had no clear winner.
"I think that at best the findings represented a draw," she says.
"The hope was that raloxifene would offer the benefits of tamoxifen without
the risks, but that isn't what happened."
In an editorial examining the RUTH findings, Stefanick writes that
identifying who should and should not take tamoxifen or Evista for breast
cancer prevention remains problematic.
"For now, there is no magic bullet that can reduce the risks of major
health problems related to estrogens and aging without introducing
other potentially serious health concerns," she wrote.
She tells WebMD that drug makers are continuing the search for a better SERM
for breast cancer prevention.
"If raloxifene is better [than tamoxifen], I believe it is just a little
bit better," she says. "And you have to remember that far more women
die from stroke than from breast
cancer. More women die from heart disease than all cancers put